FOR PATIENTS
ZeraFlow is a staff-supervised, about 30-minute in-clinic experience, designed as an alternative to traditional at-home bowel prep. Just three mild laxative tablets the night before. No liquid prep solution. No guesswork. Just show up.
Dreading the prep? There's a better way.
YOU ARE NOT ALONE
You’re Not the Problem. The prep is.
71%
of colonoscopy patients say the prep is the worst part of the entire experience. ¹
40%+
of eligible adults are not up to date on recommended colorectal cancer screenings.²
Millions
of screenings are missed every year - not because of the procedure, but what comes before it.³
This isn't a patient problem. It's a system design problem. ZeraFlow was built to change that.
What about privacy?
ZeraFlow is performed in a private room with a dedicated staff member. The process is designed to be gentle, private, and supervised from start to finish — and over in about 30 minutes, after which you go straight into your colonoscopy.
Three steps. That is all.
-

Take your tablets (the night before)
Three mild laxative tablets the night before. No liquid prep. Follow your clinic's dietary instructions. Just a light dinner.
-

Arrive at your clinic
Come in the morning of your colonoscopy as you normally would. Your care team takes it from here.
-

Complete your ZeraFlow prep
Designed to complete prep in about 30 minutes before your procedure begins.
THE DIFFERENCE
Traditional prep vs. ZeraFlow
ZeraFlow is not available everywhere yet.
ZeraFlow™ has not been cleared by the FDA and is not available for commercial use or sale in the United States. Enter your information below, and we will notify you if ZeraFlow becomes available near you. ZeraFlow is not available in all markets.
¹ Vemulapalli KC, Lahr RE, Rex DK. 2021 Patient Perceptions Regarding Colonoscopy Experience. Journal of Clinical Gastroenterology. 2023;57(4):400-403. https://pubmed.ncbi.nlm.nih.gov/35324481/
² King SC, King J, Thomas CC, Richardson LC. Baseline Estimates of Colorectal Cancer Screening Among Adults Aged 45 to 75 Years, Behavioral Risk Factor Surveillance System, 2022. Prev Chronic Dis 2025;22:250175. https://www.cdc.gov/pcd/issues/2025/25_0175.htm
³ McLachlan SA, Clements A, Austoker J. J Clin Oncol. 2009;27(Suppl):S15. https://scopubs.org/doi/10.1200/jco.2009.27.15_suppl.s15
⁴ Ziv Y, Scapa E. Techniques in Coloproctology. 2013;17:39-44. https://link.springer.com/article/10.1007/s10151-012-0876-8
⁵ In clinical evaluation, 1.6% of patients reported mild transient nausea. No severe pain or cramping was reported. Source: Ziv Y, Scapa E. Techniques in Coloproctology. 2013;17:39-44. https://link.springer.com/article/10.1007/s10151-012-0876-8 | Full side effects: see Important Safety Information page